Protocol: Effect of intravitreal bevacizumab (avastin) in the treatment of macular edema: A systematic review of randomized controlled trials

Hammad A. Qazi
Department of Health and Rehab Sciences, Faculty of Health Sciences, University of Western Ontario, London, Ontario, Canada

Cystoid macular edema (CME) is a relatively common painless condition usually accompanied by blurred vision. The prevalence of CME varied from 5% to 47% depending on cause of pathology. There are several treatments available for ME including intravitreal use of bevacizumab that has been used in different doses in few studies. However, there is still scarcity of data available on the use of bevacizumab for the treatment of ME. A systematic review is needed to provide a foundational base to discuss and synthesize the available information on the effectiveness and safety of intravitreal bevacizumab in macular edema, so that recommendations and policies can be built regarding controversial use of bevacizumab in macular edema. We have planned to perform a systematic review with an objective to compare the effects of a single injection of 1.25 mg intravitreal bevacizumab (avastin) in the improvement of visual acuity, macular edema, and thickness with other interventions/controls for the treatment of macular edema at 3 and 6 months interval using randomized controlled trials. This is only a protocol of the review and we will be conducting a full length review, addressing the issue in future.

Key words: Avastin, protocol, systematic review

INTRODUCTION

Description of the condition
Macular edema (ME) is an abnormal thickening of the macula due to accumulation of excess fluid in the extracellular space of the retina.[1] It is a leading cause of irreversible vision loss,[2] in the ocular conditions such as diabetic retinopathy,[3] venous occlusion,[4] uveitis,[5] after cataract surgery,[6] ocular inflammations, and branch retinal vein occlusion.[7] It is diagnosed by investigative tools such as fluorescein angiography (FA) and optical coherence tomography (OCT).[8] The most common forms of macular edema are cystoid macular edema and diabetic macular edema.

Cystoid macular edema (CME) is a relatively common painless condition usually accompanied by blurred vision.[1] It is diagnosed by biomicroscopy, fluorescein angiography, and/or optical coherence tomography and is observed as a fluid accumulation in multiple cyst-like spaces within macula.[1] It is frequently associated with various ocular conditions such as cataract surgery and age-related macular degeneration (ARMD).[9] The prevalence of CME varies between 5% to 47% depending on its cause of pathology such as in patients with diagnosis of uveitis, retinitis pigmentosa, pars planitis, toxocariasis, after cataract surgery, and age-related macular degeneration its prevalence is 6.1%,[10] 9.45-44%,[11,12] 26.1-27%,[13,14] 47.4%,[15] 5%,[16] and 46%,[17] respectively.

The prognosis of CME varies according to its cause. Pseudophakic CME typically has the best prognosis.[9] Similarly, CME prognosis after retinal detachment is generally without complications.[18] However, despite its good prognosis persistent macular edema or multiple remissions and exacerbations can result in foveolar photoreceptor damage with permanent impairment of vision.[9] The risk of a person having CME can be decreased by avoiding intraoperative complications in ophthalmic surgery, such as posterior capsule rupture, vitreous loss, or dislocated lens.[9]

Diabetic macular edema (DME) is a common complication of diabetic retinopathy.[19] DME can be classified into diffuse macular edema, cystoid macular edema, and serous retinal detachment on the basis of

<table>
<thead>
<tr>
<th>Access this article online</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quick Response Code:</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>DOI:</td>
</tr>
</tbody>
</table>
OCT. Diffuse macular edema is a general thickening caused by extensive capillary dilation, while focal edema is caused primarily by focal leakage from specific vascular abnormalities, diagnosed by hard exudates. The most common complication of DME is a subretinal fibrosis. Subretinal fibrosis is a vision-threatening condition that can occur in 2% of eyes with diabetic macular edema. This poor prognosis is generally even refractive to focal laser therapy (best treatment available for DME). A study by Markomichelakis et al. has shown the prevalence of DME was 54.8% in patients with macular edema. DME mostly occurs in combinations with other ocular conditions such as vitreomacular adhesion.

Macular edema is the final common phenotype of several pathophysiologic processes, and its effective management is based on the diagnosis and management of its cause. There are various treatments available for macular edema such as NSAIDS, carbonic anhydrase inhibitors, steroids, immunomodulators, hyperbaric oxygen, and vitreous surgery. Laser photocoagulation is the treatment of choice in nondiffuse macular edema, whereas pharmacological agents such as NSAIDS have shown effectiveness in decreasing diffuse macular edema and improving visual outcome. For CME a combined treatment of NSAIDs and steroids have shown faster resolution than placebo. A study has also shown that treating with NSAIDs after cataract surgery decreases the risk of postoperative CME.

**Description of the intervention**
A vascular endothelial growth factor (VEGF) is a potent inducer of vascular permeability that leads to macular edema. Bevacizumab (Avastin R, a trademark of Genentech, Inc.) is a VEGF inhibitor, which is a full length humanized monoclonal antibody IgG approved for intravenous administration for the treatment of diseases such as metastatic colorectal cancer, ovarian cancer, and glioblastoma multiforme. There are no contraindications associated with using bevacizumab IV; however, it should be given with precautions in patients with gastrointestinal perforations and hypertension. Its adverse effects include proteinuria, wound complications, thromboembolic events, and hypertensive crisis. The chemical formula of bevacizumab is C-6638 H-10160 N-1720 and its molecular mass is approximately 149 kD.

Bevacizumab has also been currently used by clinicians for treatment of choroidal neovascularization as an off-label use, as currently not approved by FDA (Food and Drug Administration, USA). Many studies conducted on intravitreal use of bevacizumab have used a quantity of 1.25 mg using a 30-gauge needle. Although, few studies have also used 2.5 mg of Avastin; however, both 1.25 and 2.5 mg have shown similar treatment efficacy. Studies on its pharmacokinetics and dynamics have shown that a half-life of 1.25 mg of intravitreally injected bevacizumab was 2.8 and 12.3 days in the aqueous humor and serum respectively. There is no information available on the metabolism, excretion, interaction, contraindications and adverse effects of intravitreal use of bevacizumab.

**How the intervention might work**
A meta-analysis conducted by Andriolo et al. in 2009 has shown that use of bevacizumab alone or in combination with other treatments for the treatment of ocular diseases is more effective than either photodynamic therapy, focal photocoagulation, or triamcinolone. Bevacizumab has a potential role not only to prevent, but also reduce retinal thickness in patients with DME. A study by Cordero et al. has found that a single intravitreal injection of bevacizumab is well tolerated and is associated with short-term improvement in visual acuity and retinal thickness in patients with CME. Few randomized studies have also shown improvement of visual acuity and reducing macular thickness in patients with DME as well as improving visual acuity in patients with CME.

However, there are few exceptions as well; a study by Picolla et al., 2008 has shown that a single intravitreal injection of triamcinolone is better than bevacizumab in the short-term management of refractory diabetic macular edema. Further, another study showed that up to 12 weeks of treatment with intravitreal bevacizumab versus laser photocoagulation in patients with DME is not associated with a significant decrease in macular thickness.

**Why it is important to do this review**
Macular edema in its various forms can be considered a leading cause of central vision loss in the developed world, and is of enormous medical and socioeconomic importance. Despite that ample studies have shown the effectiveness of bevacizumab in ocular disorders its intravitreal use is still not approved by FDA. One of the hindrances may be incomplete information regarding its metabolism, excretion, adverse effects, and drug interactions. Second, studies showing effectiveness of bevacizumab have failed to make any firm recommendations or conclusions as most of these studies were of short duration with no long-term follow ups. Further, some of the inconclusive studies were conducted on small samples without sample size determination and thus may lack the statistical power to calculate the effect size.

This issue is also important because many hospitals in different countries like Pakistan and Bangladesh and even few of the hospitals of countries such as US and UK are using this drug for ocular diseases unofficially.
A systematic review is needed to provide a foundational base to discuss and synthesize the available information on the effectiveness and safety of intravitreal bevacizumab in macular edema, so that, recommendations and policies can be built regarding controversial use of bevacizumab in macular edema.

OBJECTIVES

The primary objective is to compare the effects of a single injection of 1.25 mg intravitreal bevacizumab (avastin) in the improvement of visual acuity, macular edema and thickness with other interventions/controls for the treatment of macular edema at three and six months interval using randomized controlled trials. The secondary objective is to compare the effects of a single injection of 1.25 mg intravitreal bevacizumab (avastin) in improving foveal thickness and macular volume, visual acuity, macular edema and thickness, and complications and adverse events with other interventions/controls for the treatment of macular edema at different time intervals using randomized controlled trials.

MATERIAL AND METHODS

Selection criteria
Population
Studies enrolling participants with unilateral or bilateral macular edema of any type severity/grade irrespective of any age, gender, ethnicity, and type would be included. The justification of selection criteria is macular edema and in general has no racial, sexual, and age restricted predilection. The treatment effect of bevacizumab is not related to age and gender; however, age and gender subgroup analysis will be done keeping in view that only limited information on intravitreal use of bevacizumab is available. There are two main types of macular edema that is cystoid macular edema and diabetic macular edema for which subgroup analysis will be conducted. There is no grading criteria available for macular edema. The diagnosis of macular edema will be based on retinal thickening, and/or intraretinal cysts in the foveal region determined by either optical coherence tomography (OCT), fluorescein dye or ophthalmoscope by an ophthalmologist either in a tertiary care center or clinic.

Interventions
All studies using intravitreal bevacizumab (avastin) single injection of 1.25 mg (0.05 mL) will be included. This is a standard protocol followed in different institutions and supported by studies. Any duration and timing of delivery of avastin will be accepted. However, studies will be excluded in which Avastin will be given as co-intervention that is in combination with other treatments agents, in order to avoid issues related to contamination of the intervention.

Controls
The comparison group will be any other anti-VEGF (vascular endothelial growth factor) treatment, placebo, standard, or another intervention such as triamcinolone acetonide, laser treatment etc., Any duration, timing, frequency, and dosage of control will be accepted.

Outcomes
Primary outcomes. It includes:
1. Best corrected visual acuity either measured by Snellen chart or measured by visual acuity scale (log MAR) at 3 and 6 months.
2. Macular edema and thickness at 3 and 6 months. It will be measured by optical coherence tomography, fluorescein dye or ophthalmoscope.

Secondary outcomes. It includes:
1. Best corrected visual acuity by Snellen chart or by log MAR at 12 months.
2. Foveal thickness and macular volume measured by optical coherence tomography (MV) at 3, 6, and 12 months.
3. Macular edema and thickness at 12 months.
4. Number and types of complications within 12 months.

Adverse events
Adverse events included marked, moderate to transient anterior chamber reaction, subconjunctival hemorrhage, posterior vitreous detachment, focicular inflammation, increased intraocular pressure, retinal tears and detachment, cataract progression, and any other adverse effect within one year of treatment.

Quality of life measures and economic data
Quality of life by any validated measures would be summarized when reported in the included studies. The review will include cost effectiveness, cost benefit, and cost utility analysis if available.

Studies
All included studies will be randomized controlled trials (RCT) of any duration, follow up, number of assessments or measurements. Randomized controlled trials including either simple or permuted (blocked) randomization and using methods such as random numbers table, random assignments generated by computer, coin-tossing, throwing dice, drawing of lots, dealing previously shuffled cards, or minimization will be included. Quasi randomized controlled trials or nonrandomized controlled trials using methods such as date of birth, case record number, date of presentation,
and other nonrandom methods such as preference of clinician, preference of study participants, or availability of intervention will not be included. For studies with incomplete information or using unclear methods such as, when the authors use a word of randomization but the process was not explained such as a random number table or a computer random number generator was not specified a contact with the corresponding author would be made.

Search method for identification of studies
A search will be conducted based on key terms or MeSH descriptors of “macular edema,” “macula lutea,” “bevacizumab,” “macula* or macula* edema or diabetic macula* edema or cystoid macula* edema,” “bevacizumab* or avastin or Vascular Endothelial Growth factor or VEGF*” in Cochrane central register of controlled trials (CENTRAL) including cochrane library, Medline-ovid, EMBASE, Web of Science, CINAHL (Current Index to Nursing and Allied Health Literature) and Open SIGLE (System for Information on Grey Literature in Europe). Conference proceedings will be located from ISTP (Index to Scientific and Technical Proceedings) and INSIDE (BL database of Conference Proceedings and Journals). Thesis and dissertation will be retrieved from Index to Theses (formerly ASLIB), Australian Digital Theses Program, Canadian Theses and Dissertations, DATAD - Database of African Theses and Dissertations and Dissertation Abstract Online (USA). Ongoing trails will be searched from UK National Research Register, Meta Register of Controlled Trials (mRCT), NHS Trusts Clinical Trials Register, Medical Research Council UK, Netherlands Trial Register, Clinical Trials government and IPFMA Clinical Trials Register. There would be no date or language restrictions. For non-English articles we will contact a certified translator and for the unpublished articles and dissertations we will contact the authors. The articles would also be searched from the reference list of the studies included in the review for information about further trials. The exact key words that will be used for each of the databases along with specific search strategy are attached as Appendix 1.

Selection of studies
Two researchers will independently select and screen the titles and abstracts of the relevant articles identified by the systematic search strategies. Each researcher will independently classify the titles and abstracts of the relevant studies into include, exclude and unsure. Each researcher will also independently assess the full extract of the included and unsure articles and will further classify them into include, exclude, and unsure. For studies that will require further information we will contact the corresponding author requesting for further general descriptions. Finally both the researchers will compare their individual classifications and will discuss any discrepancies. In case of no mutual consensus in classification between the two authors, the final judgment regarding classification of studies will be made by the third researcher. The complete details of the selection criteria are attached as Appendix 2.

Data extraction and management
Two researchers would separately extract data from the selected studies into paper version of data extraction form. Any conflicts would be resolved by mutual discussion and further consulting with the third researcher if necessary. The extracted data would include reviewer, article number, author, year, funding, country, language, and reasons for exclusion. Participant characteristics included age, gender, cause and form of macular edema, duration, severity grade, diagnostic criteria used that is OCT, fluorescein dye or ophthalmoscope and other co-morbid conditions would be recorded. Information regarding interventions and controls such as bevacizumab timing and duration, type of comparator or control, its dose, frequency, mode of delivery, duration, and timing will be noted. Sample size, methodological characteristics such as allocation concealment, blindness of patients, clinicians and outcome assessors, lost to follow up or missing data, selective outcome reporting, and other sources of bias will be recorded. Primary and secondary outcomes, adverse events, quality of life data and any economical data along with statistical analysis techniques will also be recorded. The extracted data will be entered into Review Manager Software (Rev Man 5) by one of the reviewer and the other reviewer will verify the entries.

Assessment of risk of bias in included studies
Two researchers will assess risk of bias in included studies by using an assessment tool mentioned in Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions.\(^{[60]}\) The criteria will include allocation concealment, blindness of patients, clinicians and outcome assessors, missing outcome data, selective outcome reporting, and other sources of bias. Each reviewer will assess article on the basis of above characters and categorize each parameter into adequate, inadequate or unclear methods. Any discrepancies on grading would be solved by mutual discussion and consensus.

Measurement of treatment effect
Treatment effects will be measured in terms of types of data used in the studies following Deeks.\(^{[64]}\)

Dichotomous data. It includes proportion of patients with improvement in best corrected visual acuity by three or more lines (equivalent of 15 letters), macular edema and thickness, foveal thickness and macular volume at 3, 6, and 12 months, adverse events and complications within 1 year. The type of macular edema will also be reported as dichotomous data. The dichotomous variables will be
reported as risk ratios with 95% confidence intervals.

Continuous data. The continuous data includes changes in visual acuity (log MAR), macular edema and thickness, foveal thickness, and macular volume at 3, 6, and 12 months. The continuous data will be reported either in mean (SD) or median (IQR) depending on assumptions of normality and weighted mean difference.[65]

Ordinal data. The number of complications and adverse events, economic data and quality of life, and grading of macular edema would be reported as ordinal data or rates data.

Counts data. The number of times adverse events and complications occurred within a person would also be given as counts data.

Unit of analysis issues. The unit of analysis will be the eye of an individual participation.[66] Most of the trials included will randomize a single eye or both eyes to the intervention.[67] If both eyes of a single participant are randomized to a single intervention, then each eye will be treated.[67] Crossover trials will be meta analyzed separately irrespective of whether they are also combined together and a sensitivity analysis will be conducted to support the results of how cross over trials were conducted.[68] Studies with co intervention and multi intervention will be excluded. Repeated assessments will be done at 3, 6, and 12 months.[69] For events that may reoccur within a single patient count data analysis will be conducted.[69]

Missing outcomes
Any missing data on the required outcomes would be gathered by contacting the corresponding author. For data that cannot be retrieved a multiple imputation method would be used and a sensitivity analysis would be applied to determine the potential impact of missing data in our results.[66] The potential impact of missing data will be also discussed in the discussion section.[66]

Heterogeneity, subgroup analysis, data analysis, and sensitivity analysis
There is no evidence is available on the effect of bevacizumab in relation to age and gender; therefore, clinical diversity would not be of issue. However, a subgroup analysis would be performed to measure the effect of type of macular edema as well as affect of age and gender. Methodological diversity would be minimized by selecting only a single study design (RCT) and also by performing sensitivity analysis for the methodological quality of studies. However, as some argue argue that, since clinical and methodological diversity always occur in a meta-analysis, statistical heterogeneity is inevitable.[69] Therefore, heterogeneity will be addressed by using the I-squared test to assess the impact of intervention variability in different studies. Random-effect model would be used in the case of more than three trials and fixed effects in case of less than three trials.[65] In the case of heterogeneity value greater than 50%, meta analysis would not be performed and results will be presented in the tabular format.[65] However, investigations for heterogeneity of individual studies in terms of subgroup analysis or meta-regression would not be done in case of small number of studies.[67] Funnel plots would be used to assess the other means of heterogeneity only if more than 10 studies would be found.[66] Finally a sensitivity analysis will be performed to determine the impact of quality of studies on the findings.

APPENDIX 1

Search strategies

Central
1. MeSH descriptor Macular Edema
2. MeSH descriptor Macula Lutea
3. MeSH descriptor Bevacizumab
4. macula* or macula* edema or Diabetic macula* edema or cystoid macula* edema
5. bevacizumab* or avastin or Vascular Endothelial growth factor or VEGF*
6. 1 or 2 or 3
7. 6 and 5
8. 4 and 5

Medline - OVID
2. Bevacizumab.mp. Or Vascular Endothelial Growth Factor A
3. Vascular Endothelial Growth Factor A/or Avastin.mp.
4. Macular Edema/or Macula* Edema.mp. Or Macula Lutea
5. Macular Edema/or Diabetic Retinopathy/or Diabetic macula* edema.mp. Or Macula Lutea
6. Macular Edema/or cystoid macula* edema.mp.
7. (Intravitreal Bevacizumab or Intravitreal Avastin). mp. [mp = title, original title, abstract, name of substance word, subject heading word, unique identifier]
8. 4 and 7
9. 1 and 8
10. 2 or 3 or 7
11. 1 and 10
12. 4 and 10
13. 1 and 12
14. 4 or 5 or 6
15. 10 and 14
16. 1 and 15

Embase
1. Random$ or Random Allocation
2. Macula$ or macula$ edema or cystoid macula$ edema or diabetic macula$ edema
3. Bevacizumab or avastin or vascular endothelial growth factor or VEGFS$
4. 1 and 2
5. 1 and 3
6. 2 and 3
7. 1 and 2 and 3

Cinahl
1. Macula$\text{g}$ or macula$\text{s}$ edema or cystoid macula$\text{s}$ edema or diabetic macula$\text{s}$ edema
2. Bevacizumab or avastin or vascular endothelial growth factor or VEGF$\text{g}$
3. 1 and 2

Open SIGLE (System for Information on Grey Literature in Europe)
1. Macula* or macula* edema or diabetic macula * edema or cystoid macula* edema
2. Bevacizumab or avastin or vascular endothelial growth factor or VEGF*
3. 1 and 2

Web of Science
Bevacizumab or Avastin and macular edema

ISTP, INSIDE, Index to Theses (formerly ASLIB), Australian Digital Theses Program, Canadian Theses and Dissertations, DATAD, UK National Research Register, Meta Register of Controlled trials, NHS Trusts Clinical Trials Register, Medical Research Council UK, Netherlands Trial Register, Clinical Trials government and IPFMA Clinical trials Register.

Bevacizumab and macular edema

APPENDIX 2

Relevance tool
Study ID:-----------------------------Y/N

Reviewer ID:-----------------------------

Date of Review:-----------------------------

Study design: -----------------------------Y/N/Unclear

The study included a randomized controlled trial of any duration or follow up. Sequence Generation. Either simple or permuted (blocked) randomization including adequate methods such as random numbers table, random assignments generated by computer, or minimization etc.[61,62] Inadequate methods of randomization include quasi-randomized methods such as date of birth and other non-random methods such as preference of clinician etc. The unclear measures would be when the author’s use the words of “randomization”, but the process was not explained or was not specified.

Participants: -----------------------------Y/N

The study includes participants of either unilateral or bilateral “Macular Edema” of any severity/grade type and of any age, gender, and ethnicity. The participants have diagnosis of “Macular Edema” by either optical coherence tomography (OCT), fluorescein dye or opthalmoscope.

Intervention: -----------------------------Y/N

The participants were offered single injection of 1.25 mg (0.05 mL) intravitreal bevacizumab (avastin) with no co-intervention.

Comparator or control: -----------------------------Y/N

The studies included comparison groups including other anti-VEGF (vascular endothelial growth factor) treatment, placebo, standard, or another intervention.

Outcome measures:

The study has one or more of the following outcomes: Y/N
- Best corrected visual acuity by Snellen chart or (log MAR).
- Macular edema and thickness.
- Adverse outcomes of Iris neovascularization or anterior chamber reaction or other adverse outcomes.
- Number and types of complications.
- Cost effective, cost benefit or cost utility analysis.
- Quality of life data.

Reviewer decision (Yes to all criteria):-----------------------------Y/N

Reviewer agreements:-----------------------------Y/N

Comments:

Final decision: -----------------------------Y/N

REFERENCES


